The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
Sign in to access this content
Sign InEvercore ISI Group has increased its price target for Quest Diagnostics (DGX) to $220, up from the previous $190. This adjustment reflects a significant 15.79% rise, signaling the firm's confidence in the company's growth prospects. Despite this optimistic revision, Evercore ISI maintained an "In-Line" rating for the stock. Countering this view, GuruFocus estimates a potential downside for DGX based on its GF Value fair value calculation. This divergence highlights a mixed outlook, where strong analyst confidence is tempered by valuation concerns. Investors will likely weigh both the upward target revision and the potential valuation risks when assessing DGX.